292 related articles for article (PubMed ID: 23234803)
21. Functional polymorphisms in FAS and FASL contribute to risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population.
Wang J; Gao J; Li Y; Zhao X; Gao W; Peng L; Yan D; Liu L; Li D; Wei L; Qi J; Zhou C
Gene; 2013 Jul; 524(2):193-6. PubMed ID: 23618817
[TBL] [Abstract][Full Text] [Related]
22. The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes.
Li Y; Zhang HL; Kang S; Zhou RM; Wang N
Gynecol Oncol; 2017 Jan; 144(1):140-145. PubMed ID: 27836206
[TBL] [Abstract][Full Text] [Related]
23. [Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer].
Yang S; Miao XP; Zhang XM; Sun T; Qu SN; Xiong P; Ye YJ; Guo YL; Tan W; Wang S; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2132-5. PubMed ID: 16313826
[TBL] [Abstract][Full Text] [Related]
24. IL6 and FAS/FASL gene polymorphisms may be associated with disease progression in HIV-1-positive ethnically mixed patients.
Loureiro Dos Reis MM; Queiroz MAF; da Silva BCM; da Silva Duarte AJ; Casseb J; Arganaraz GA; Vallinoto ACR; Argañaraz ER
J Med Virol; 2020 Aug; 92(8):1148-1157. PubMed ID: 31825106
[TBL] [Abstract][Full Text] [Related]
25. Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis.
Yıldır S; Sezgin M; Barlas IÖ; Türköz G; Ankaralı HÇ; Şahin G; Erdal ME
Rheumatol Int; 2013 Oct; 33(10):2637-45. PubMed ID: 23749041
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms in
Si W; Kang S; Sun H; Chen J; Cao S; Li Y
Int J Gynecol Cancer; 2019 Sep; 29(7):1148-1155. PubMed ID: 31273068
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions.
Hsu PI; Lu PJ; Wang EM; Ger LP; Lo GH; Tsay FW; Chen TA; Yang HB; Chen HC; Lin WS; Lai KH
Anticancer Res; 2008; 28(1A):97-103. PubMed ID: 18383830
[TBL] [Abstract][Full Text] [Related]
28. The diplotype Fas -1377A/-670G as a genetic marker to predict a lower risk of breast cancer in Chinese women.
Xu Y; Deng Q; He B; Pan Y; Li R; Gao T; Sun H; Song G; Wang S; Cho WC
Tumour Biol; 2014 Sep; 35(9):9147-61. PubMed ID: 24916571
[TBL] [Abstract][Full Text] [Related]
29. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
[TBL] [Abstract][Full Text] [Related]
30. Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population.
Park SH; Choi JE; Kim EJ; Jang JS; Lee WK; Cha SI; Kim CH; Kam S; Kim DS; Park RW; Kim YC; Han SB; Jung TH; Park JY
Lung Cancer; 2006 Dec; 54(3):303-8. PubMed ID: 17014925
[TBL] [Abstract][Full Text] [Related]
31. The Associations of Genetic Variants in E-cadherin Gene With Clinical Outcome of Epithelial Ovarian Cancer.
Juan W; Shan K; Na W; Rong-Miao Z; Yan L
Int J Gynecol Cancer; 2016 Nov; 26(9):1601-1607. PubMed ID: 27779545
[TBL] [Abstract][Full Text] [Related]
32. FAS promoter polymorphisms and serum sFas level are associated with increased risk of nerve damage in Bangladeshi patients with Guillain-Barré syndrome.
Islam Z; Jahan I; Ahammad RU; Shahnaij M; Nahar S; Mohammad QD
PLoS One; 2018; 13(2):e0192703. PubMed ID: 29432441
[TBL] [Abstract][Full Text] [Related]
33. FAS -1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer.
Kang S; Dong SM; Seo SS; Kim JW; Park SY
Cancer Genet Cytogenet; 2008 Jan; 180(1):1-5. PubMed ID: 18068525
[TBL] [Abstract][Full Text] [Related]
34. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction.
Lai HC; Lin WY; Lin YW; Chang CC; Yu MH; Chen CC; Chu TY
Gynecol Oncol; 2005 Oct; 99(1):113-8. PubMed ID: 15996722
[TBL] [Abstract][Full Text] [Related]
35. Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.
Daripally S; Nallapalle SR; Katta S; Prasad VV
Tumour Biol; 2015 Sep; 36(10):7817-30. PubMed ID: 25944167
[TBL] [Abstract][Full Text] [Related]
36. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.
Zhou RM; Wang N; Chen ZF; Duan YN; Sun DL; Li Y
J Gastroenterol Hepatol; 2010 Mar; 25(3):555-61. PubMed ID: 20074157
[TBL] [Abstract][Full Text] [Related]
37. Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies.
Xu Y; He B; Li R; Pan Y; Gao T; Deng Q; Sun H; Song G; Wang S
PLoS One; 2014; 9(3):e90090. PubMed ID: 24598538
[TBL] [Abstract][Full Text] [Related]
38. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
[TBL] [Abstract][Full Text] [Related]
39. Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.
Edathara PM; Gorre M; Kagita S; Vuree S; Cingeetham A; Nanchari SR; Meka PB; Annamaneni S; Digumarthi RR; Satti V
Tumour Biol; 2016 Apr; 37(4):5475-84. PubMed ID: 26563376
[TBL] [Abstract][Full Text] [Related]
40. Fas/Fas Ligand pathways gene polymorphisms in pediatric renal allograft rejection.
Fadel FI; Elshamaa MF; Salah A; Nabhan M; Rasheed M; Kamel S; Kandil D; Thabet EH
Transpl Immunol; 2016 Jul; 37():28-34. PubMed ID: 27109035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
